PULM

Pulmatrix Inc. (PULM) | Rumor.io

Pulmatrix

PULM

Attention (50-day avg)0%

Attention rank (50-day avg)#3,346

Bullish sentiment (50-day avg)94%

Price to earnings ratio-1.13

Market capitalization5.8M

Earnings per share-1.1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-5.2M

Social

What share of all stock conversation is about PULM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 18

$PULM has seen significant trading volume, with some users noting it's the most they've seen in a while.
There are differing opinions on the stock, with some users speculating about insider knowledge and others expressing skepticism.
The stock's price has fluctuated, with some users noting it's been moving quickly and others commenting on its potential for a further drop.

Generated by AI

Sentiment

Of the messages about PULM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	93.94% -6.06	81.44% +6.01
Bearish	—	—	6.06% +6.06	18.56% -6.01

Bullish· Mar 26

Pulmatrix, Inc. (PULM) has seen the bottom and is poised for a bounce.
PULM has significant news out that could lead to a substantial price increase.
The stock is likely to experience a big run and could potentially reach $5.

Bearish· Mar 26

The merger with Eos is a dilutive takeover, where current shareholders will own only ~6% of the new company, and the stock price may drop due to the high-risk nature of the biotech.
The company's pipeline, including PUR1900 and ISPERSE, may be abandoned or shelved, as the merger prioritizes Eos's assets over Pulmatrix's existing drugs.
The assets being sold or partnered would have already been done if they had real value, and the reverse merger indicates that Pulmatrix's assets are not valuable on their own.

Generated by AI

Topics

Of the messages about PULM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	48.65%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	51.35%

Announcements· Nov 14

Pulmatrix, Inc. (PULM) has merged with Cullgen, creating a company with $65M in cash and three Phase 1 clinical trials in its pipeline.
The merger is expected to accelerate the commercial participation of iSPERSE, a platform with 1/10th the dosage and 20x + efficacy, improving safety as a result.
The combined company's strong Chinese base and connections with Japanese investors could lead to significant growth, making it an interesting investment opportunity.

Technical Analysis· Aug 25

The middle Bollinger Band at $4.93 is a key level for $PULM to close above and turn into support, potentially initiating a new uptrend and a run to the 50-week moving average at $8.36.
$PULM has resistance near $6.15, $6.35, $6.58, and $6.85, and support near $5.78, $5.55, $5.30, and $5.21.
The RSI is positive and the MACD has just crossed up, indicating a potential bullish signal for $PULM, with a decent setup pattern and a risk-reward opportunity.

Generated by AI

Community

Of the messages about PULM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	9.52%	51.9%
Newcomers	—	75%	90.48%	48.1%

Regulars· Jan 4

The company has announced positive top line results from a Phase 1 study with PUR3100, a novel orally inhaled dihydroergotamine (DHE), for acute migraine.
The study is a rerun of a trial by Allergan that failed at phase 3, but Pulmatrix has tweaked the formulation with isperse and will use a better delivery device.
The stock has shown a significant increase in price, up 10.46% at $3.59 in the last 13 minutes, with a high volume of 655k and an average volume of 29k.

Newcomers· Nov 18

Many newcomers are excited about Pulmatrix, Inc. reaching new 52-week highs and are optimistic about its future.
Some new investors are considering buying Pulmatrix, Inc. due to its potential for special dividends and its relatively low price.
A few newcomers are observing the stock's uptrending chart and considering it for investment based on its technical analysis.

Generated by AI

Also Discussed

Investors talking about PULM also mention

#	Name	Attention
1	AB Corporate Bond ETFEYEG	0%0
2	Globus Maritime Limited Common StockGLBS	0%new
3	Tenax Therapeutics, Inc.TENX	0%+0
4	BLPH - Bellerophon Therapeutics, Inc.	——
5	Benitec Biopharma LtdBNTC	0%new
6	EVOK - Evoke Pharma, Inc.	——
7	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
8	Euroseas Ltd.ESEA	0%0
9	Akari Therapeutics Plc ADRAKTX	0%0
10	MRNS - Marinus Pharmaceuticals, Inc.	——

Pulmatrix Inc.

Healthcare
Biotechnology

Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use. Pulmatrix’s current product candidates address serious conditions with unmet medical needs, including chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, and acute migraine. Its research and development activity is concentrated on creating inhaled formulations that may improve drug delivery efficiency and patient tolerability. Based in Framingham, Massachusetts, Pulmatrix operates within the biotechnology and pharmaceutical sectors, where it contributes to the development of specialized pulmonary-delivered therapeutics.

Website

Location

945 Concord Street

Framingham, MA, 01701

United States

Social

What share of all stock conversation is about PULM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 18

$PULM has seen significant trading volume, with some users noting it's the most they've seen in a while.
There are differing opinions on the stock, with some users speculating about insider knowledge and others expressing skepticism.
The stock's price has fluctuated, with some users noting it's been moving quickly and others commenting on its potential for a further drop.

Generated by AI

Sentiment

Of the messages about PULM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	93.94% -6.06	81.44% +6.01
Bearish	—	—	6.06% +6.06	18.56% -6.01

Bullish· Mar 26

Pulmatrix, Inc. (PULM) has seen the bottom and is poised for a bounce.
PULM has significant news out that could lead to a substantial price increase.
The stock is likely to experience a big run and could potentially reach $5.

Bearish· Mar 26

The merger with Eos is a dilutive takeover, where current shareholders will own only ~6% of the new company, and the stock price may drop due to the high-risk nature of the biotech.
The company's pipeline, including PUR1900 and ISPERSE, may be abandoned or shelved, as the merger prioritizes Eos's assets over Pulmatrix's existing drugs.
The assets being sold or partnered would have already been done if they had real value, and the reverse merger indicates that Pulmatrix's assets are not valuable on their own.

Generated by AI

Topics

Of the messages about PULM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	48.65%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	51.35%

Announcements· Nov 14

Pulmatrix, Inc. (PULM) has merged with Cullgen, creating a company with $65M in cash and three Phase 1 clinical trials in its pipeline.
The merger is expected to accelerate the commercial participation of iSPERSE, a platform with 1/10th the dosage and 20x + efficacy, improving safety as a result.
The combined company's strong Chinese base and connections with Japanese investors could lead to significant growth, making it an interesting investment opportunity.

Technical Analysis· Aug 25

The middle Bollinger Band at $4.93 is a key level for $PULM to close above and turn into support, potentially initiating a new uptrend and a run to the 50-week moving average at $8.36.
$PULM has resistance near $6.15, $6.35, $6.58, and $6.85, and support near $5.78, $5.55, $5.30, and $5.21.
The RSI is positive and the MACD has just crossed up, indicating a potential bullish signal for $PULM, with a decent setup pattern and a risk-reward opportunity.

Generated by AI

Community

Of the messages about PULM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	9.52%	51.9%
Newcomers	—	75%	90.48%	48.1%

Regulars· Jan 4

The company has announced positive top line results from a Phase 1 study with PUR3100, a novel orally inhaled dihydroergotamine (DHE), for acute migraine.
The study is a rerun of a trial by Allergan that failed at phase 3, but Pulmatrix has tweaked the formulation with isperse and will use a better delivery device.
The stock has shown a significant increase in price, up 10.46% at $3.59 in the last 13 minutes, with a high volume of 655k and an average volume of 29k.

Newcomers· Nov 18

Many newcomers are excited about Pulmatrix, Inc. reaching new 52-week highs and are optimistic about its future.
Some new investors are considering buying Pulmatrix, Inc. due to its potential for special dividends and its relatively low price.
A few newcomers are observing the stock's uptrending chart and considering it for investment based on its technical analysis.

Generated by AI

Pulmatrix

Social

Jun 18

Sentiment

Bullish· Mar 26

Bearish· Mar 26

Topics

Announcements· Nov 14

Technical Analysis· Aug 25

Community

Regulars· Jan 4

Newcomers· Nov 18

News

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Also Discussed

Pulmatrix Inc.

Company Information

Location

News

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Also Discussed

Social

Jun 18

Sentiment

Bullish· Mar 26

Bearish· Mar 26

Topics

Announcements· Nov 14

Technical Analysis· Aug 25

Community

Regulars· Jan 4

Newcomers· Nov 18